Nutex Health Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Basic and diluted earnings (loss) per share: | |||||||||||||||||
| Numerator: | |||||||||||||||||
| Net income (loss) attributable to common stockholders | $ | 70,789 | $ | 52,097 | $ | (45,787) | |||||||||||
| Denominator: | |||||||||||||||||
| Weighted average shares used to compute basic and diluted EPS | 6,361,427 | 5,090,787 | 4,408,320 | ||||||||||||||
| Basic earnings (loss) per share: | $ | 11.13 | $ | 10.23 | $ | (10.39) | |||||||||||
| Diluted earnings (loss) per share: | |||||||||||||||||
| Numerator: | |||||||||||||||||
| Dilutive net income (loss) attributable to common stockholders | 70,789 | 53,227 | (45,787) | ||||||||||||||
| Denominator: | |||||||||||||||||
| Weighted average shares used to compute basic EPS | 6,361,427 | 5,090,787 | 4,408,320 | ||||||||||||||
| Dilutive effect of convertible note | — | 179,500 | — | ||||||||||||||
| Dilutive effect of common stock warrants | 84,695 | 53,186 | — | ||||||||||||||
| Dilutive effect of unvested restricted stock | 108,854 | 44,511 | — | ||||||||||||||
| Dilutive effect of contingently issuable shares | 201,132 | 123,692 | — | ||||||||||||||
| Weighted average shares used to compute diluted EPS | 6,756,108 | 5,491,676 | 4,408,320 | ||||||||||||||
| Diluted earnings (loss) per share: | $ | 10.48 | $ | 9.69 | $ | (10.39) | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 5, 2026 | Showing above |
| 2024 | Mar 31, 2025 | |
| 2023 | Mar 29, 2024 | |
| 2022 | Mar 3, 2023 | |
| 2021 | Mar 31, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.